PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing
Closed Pre-Solicitation Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- N01CN77019-18
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N91019D00013-75N91019F00129 Federal contract award
- Awardee
- IIT Research Institute
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- Not on record
- Place of performance
- Contractor's Facility, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health intends to award multiple Indefinite Delivery/Indefinite Quantity contracts to support the PREVENT Cancer Preclinical Drug Development Program. The solicitation seeks proposals for three pools of services: preclinical efficacy and biomarker evaluation, preclinical Good Manufacturing Practice product development and manufacturing, and toxicology and pharmacology testing. Offerors must demonstrate expertise in the applicable service areas. Up to 20 IDIQ contracts will be awarded across the three pools, each with a five year base period and potential five year option periods for task orders. Proposals are due by 3:00 pm ET on June 21, 2018.
There is no set-aside designation. The primary NAICS codes are 541715 and 541712, with the predominant PSC code R408. Current contractors may include Charles River Laboratories and WuXi AppTec. Each base IDIQ is valued between $1-5M annually with task order ceilings up to $50M over the life of the contract. Task orders will require services such as preclinical drug testing on 50-100 agents annually across 50-150 studies.
Notice text
Please see the attached documents related to the Presolicitation Notice for RFP No. N01CN77019-18 "PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing".
Files
| File | Type | Posted |
|---|---|---|
| Presolicitation_Notice_FINAL.pdf | ||
| Attach_3_of_4_CGMP_IDIQ_SOW.pdf | ||
| Attach_1_or_4_Background_Intro.pdf | ||
| Attach_2_of_4_Efficacy_IDIQ_SOW.pdf | ||
| Attach_4_of_4_Tox_IDIQ_SOW.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| PREVENT Cancer Preclinical Drug Development Program | Award Notice | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Pre-Clinical Models of Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside | |
| 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity